Abstract:C1 inhibitor therapy improves outcome in several animal models of inflammatory disease. These include sepsis and Gram negative endotoxin shock, vascular leak syndromes, hyperacute transplant rejection, and ischemia-reperfusion injury. Furthermore, some data suggest a beneficial effect in human inflammatory disease. In many inflammatory conditions, complement system activation plays a role in pathogenesis. The contact system also very likely is involved in mediation of damage in inflammatory disease. Therefore, the beneficial effect of C1 inhibitor has been assumed to result from inhibition of one or both of these systems. Over the past several years, several other potential anti-inflammatory effects of C1 inhibitor have been described. These effects do not appear to require protease inhibition and depend on non-covalent interactions with other proteins, cell surfaces or lipids. In the first, C1 inhibitor binds to a variety of extracellular matrix components including type IV collagen, laminin, entactin and fibrinogen. The biologic role of these reactions is unclear, but they may serve to concentrate C1 inhibitor at extravascular inflammatory sites. The second is a non-covalent interaction with C3b that results in inhibition of formation of the alternative pathway C3 convertase, a function analogous to that of factor H. The third is an interaction with E and P selectins on endothelial cells that is mediated by the Lewis(x) tetrasaccharides that are expressed on C1 inhibitor. These interactions result in suppression of leukocyte rolling and transmigration. The fourth interaction is the binding of C1 inhibitor to Gram negative bacterial endotoxin that results in suppression of endotoxin shock by interference with the interaction of endotoxin with its receptor complex on macrophages. Lastly, C1 inhibitor binds directly to Gram negative bacteria, which leads to suppression of the development of sepsis, as demonstrated in the cecal ligation and puncture model. These observations suggest that C1 inhibitor is a multi-faceted anti-inflammatory protein that exerts its effects through a variety of mechanisms including both protease inhibition and several different non-covalent interactions that are unrelated to protease inhibition.

Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-Phenylpiperazin-1-yl)Pyridine-3-Carboximidamide and Chemical Analogs

Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system

Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities

Anti-Vascular Permeability Of The Cleaved Reactive Center Loop Within The Carboxyl-Terminal Domain Of C1 Inhibitor

Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives As Inhibitors of Complement

C1 inhibitor: biologic activities that are independent of protease inhibition.

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Complement C1s as a diagnostic marker and therapeutic target: Progress and propective

Suppression of complement regulatory protein C1 inhibitor in vascular endothelial activation by inhibiting vascular cell adhesion molecule-1 action.

CG001, a C3b-targeted complement inhibitor blocks three complement pathways: development and preclinical evaluation

Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors

Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein

Molecular Interactions Required for Activation of Complement Component C2 Include Exosites Located on the Serine Protease Domain of C1s and Mannose-Binding Lectin Associated Protease-2

Characterization of A Small Molecule Pai-1 Inhibitor, Zk4044

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

Distinctive Binding Modes and Inhibitory Mechanisms of Two Peptidic Inhibitors of Urokinase-Type Plasminogen Activator with Isomeric P1 Residues.

Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity.

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5

Synthesis and Biological Evaluation of Menthol-Based Derivatives As Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)

Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727

Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by A Small-Molecule Antagonist